Intuitive Surgical Inc (ISRG) Surgical Robotics Growth Outlook

In reported USD figures, Intuitive Surgical generated revenue of about USD 10.06 billion for the year ended December 2025, representing 20.5% growth from the prior year. EBIT reached roughly USD 2.95 billion and net income USD 2.88 billion, indicating strong profitability.

Depreciation and amortization totaled USD 614.7 million, matching capital expenditure, while the free‑cash‑flow proxy excluding working capital changes was approximately USD 2.51 billion. The company held USD 3.37 billion in cash, and total debt was not provided.

On a trailing‑twelve‑month basis, operating margin stood at 29.27% and net profit margin at 28.38%. Return on equity was 16.36%, and the gross margin remained high at 66%, reflecting efficient operations and pricing power.

The beta of 1.65 suggests higher volatility relative to the market, but the company’s consistent margins and cash generation highlight its durable business model.

At a current share price of USD 477.73, the market values Intuitive Surgical well above its discounted‑cash‑flow estimate. The DCF model’s fair‑value range spans from USD 119.72 to USD 269.38 per share, indicating that investors are pricing in sustained growth and resilience.

With a trailing P/E of 59.83 and ROE of 16.36%, the valuation implies expectations of continued expansion and strong profitability. The premium suggests confidence in the company’s ability to maintain leadership in robotic surgery.